BACKGROUND: NUT midline carcinoma is a rare and aggressive genetically characterized subtype of squamous cell carcinoma frequently arising from the head and neck. The characteristics and optimal management of head and neck NUT midline carcinoma (HNNMC) are unclear. METHODS: A retrospective review of all known cases of HNNMC in the International NUT Midline Carcinoma Registry as of December 31, 2014, was performed. Forty-eight consecutive patients were treated from 1993 to 2014, and clinicopathologic variables and outcomes for 40 patients were available for analyses; they composed the largest HNNMC cohort studied to date. Overall survival (OS) and progression-free survival (PFS) according to patient characteristics and treatment were analyzed. RESULTS: This study identified a 5-fold increase in the diagnosis of HNNMC from 2011 to 2014. The median age was 21.9 years (range, 0.1-81.7 years); the male and female proportions were 40% and 60%, respectively; and 86% had bromodomain containing 4-nuclear protein in testis (BRD4-NUT) fusion. The initial treatment was initial surgery with or without adjuvant chemoradiation or adjuvant radiation (56%), initial radiation with or without chemotherapy (15%), or initial chemotherapy with or without surgery or radiation (28%). The median PFS was 6.6 months (range, 4.7-8.4 months). The median OS was 9.7 months (range, 6.6-15.6 months). The 2-year PFS rate was 26% (95% confidence interval [CI], 13%-40%). The 2-year OS rate was 30% (95% CI, 16%-46%). Initial surgery with or without postoperative chemoradiation or radiation (P 5.04) and complete resection with negative margins (P 5.01) were significant predictors of improved OS even after adjustments for age, tumor size, and neck lymphadenopathy. Initial radiation or chemotherapy and the NUT translocation type were not associated with outcomes.
INTRODUCTION
NUT midline carcinoma (NMC) is a rare and aggressive genetically defined subtype of squamous cell carcinoma characterized by chromosomal rearrangement of the nuclear protein in testis (NUT) gene (also known as NUTM1 or Chr15orf55). 1 The characteristic somatic t (15:19) translocation that positions NUT in frame with bromodomain containing 4 (BRD4), a ubiquitously expressed transcriptional coactivator, was first identified in 2003 . 2 Approximately 30% of NMCs lack BRD4 rearrangement and are termed NUT variants: NUT is often fused to bromodomain containing 3 (BRD3), 3 or NUT is fused to a non-bromodomain containing (BRD) gene such as NSD3. 4 NMCs are poorly differentiated tumors that display variable degrees of squamous differentiation. The diagnosis is made by the demonstration of NUT rearrangement by molecular analysis, including reverse transcriptase-polymerase chain reaction, fluorescence in situ hybridization, and cytogenetic analysis. 1 Alternatively, an immunohistochemical stain with a monoclonal antibody to NUT (C52; Cell Signaling) has been shown to be 100% specific and 87% sensitive for the diagnosis of NMC. 5 Thus, a positive NUT immunohistochemical stain by itself is diagnostic of NMC. 6 NMC is considered the most clinically aggressive type of squamous carcinoma, and the majority of patients will succumb to rapid disease progression with early metastases to locoregional and distant sites. More than 80% of patients will die within 1 year of their diagnosis despite intensive treatment, and this underscores the need for effective treatment of this disease. 7 NMC typically arises from the midline structures of the thorax or from the head and neck (HN). NMC was initially described in children and adolescents; however, in recent years, there has appeared to be an increasing frequency of diagnosis in adults. 7 The actual NMC incidence is unclear, and it is almost certainly underdiagnosed. Up to 18% of undifferentiated carcinomas of the HN are, in fact, NMC. 8, 9 In vitro studies of NMC have demonstrated that NUT fusion proteins drive tumor growth and the blockade of differentiation through aberrant histone acetylation in a manner dependent on the targeting of MYC and TP63 genes by BRD bromodomains. 3, [10] [11] [12] In a unique mechanism, the acetyl-histone-binding bromodomains of BRD4 tether NUT to chromatin; this drives acetylation of massive regions of chromatin through the recruitment of p300, a histone acetyltransferase, by NUT. These so-called megadomains trigger the transcription of underlying genes both directly and through the activation of their entire regulatory domains, including enhancers; this enforces the expression of key oncoproteins such as MYC, p63, and MED24. 10 Small-molecule Bromodomain and Extra-Terminal (BET) bromodomain inhibitors targeting BRD4-NUT are in development, and NMC patients are being enrolled in clinical trials. Although an initial report indicates that at least 1 of these drugs, OTX015 (OncoEthix/Merck), appears to have some efficacy as a single agent in human NMC, it is unclear at this stage whether this drug class alone is more effective than other conventional strategies because of limited patient numbers and a lack of clinical trial data. 13 For more than a decade, we have served as the primary diagnostic center for NMC, and in 2010, we established the International NUT Midline Carcinoma Registry to analyze clinical and pathologic data in aggregate to inform the natural history, therapeutic interventions, and outcomes. We previously reported on 63 NMC cases for which the overall median survival was 6.7 months. 7 Slightly better outcomes were observed for patients with head and neck NUT midline carcinoma (HNNMC; n 5 19) versus thoracic NMC in that cohort. 7 Since 2012, the registry has accrued more NMC cases, particularly ones arising from the HN (n 5 29). To define preferred management strategies, we sought to determine the clinical presentation, treatment and outcomes of 48 patients with HNNMC from the registry. The clinicopathologic features, treatment regimens, and outcomes of 40 evaluable patients with HNNMC are reported herein.
MATERIALS AND METHODS

International NUT Midline Carcinoma Registry
The International NUT Midline Carcinoma Registry was created in 2010, and NMC patients in this study who were enrolled were identified by referral as part of their consultation for clinical care for either diagnosis or treatment. Patients were not identified by literature searches or added from published cases. NMC patients before 2010 were identified similarly through referral or through the screening of archival pathology specimens at one of our institutions, 9,14 and they were retrospectively enrolled into the International NUT Midline Carcinoma Registry. The number of patients retrospectively enrolled before 2010 was 19, and the number of patients prospectively enrolled in 2010 or later was 29. The registry is international; enrolled patients have come from North America, South America, Europe, Asia, and Australia. There are no geographic restrictions to enrollment in the registry.
Patients
From January 1993 to December 2014, we identified 48 patients with HNNMC among a total of 107 patients (45%) in the International NUT Midline Carcinoma Registry. HNNMC patients were defined as those with tumors originating in the HN that exhibited aberrant NUT expression demonstrated by immunohistochemistry, NUT rearrangement shown by fluorescent in situ hybridization, BRD4-NUT fusion shown by reverse transcriptase-polymerase chain reaction, or cytogenetic t (15;19) in the setting of carcinoma.
1 Histology and immunohistochemistry were reviewed for all cases by Christopher A. French. Nineteen of these 48 patients were reported in our previous study, 7 and 29 were not previously reported.
A registry questionnaire was sent to treating physicians; it inquired about demographic, clinical, treatment, and outcome variables. Outcome data were provided for 40 patients. Approval of the International NUT Midline Carcinoma Registry (http://www.nmcregistry.org/), including the retrospective and prospective analysis of NMC patient data, was obtained from the institutional review board of the Dana-Farber Cancer Institute (Boston, Mass). Written informed consent was obtained from all study participants.
Patient data, including demographics, clinical staging data (site of the primary tumor, lymph node involvement, and location of the metastasis), therapeutic interventions, and responses to treatment, were abstracted from questionnaires completed by the treating physician and were analyzed in aggregate. The initial therapy was defined as the treatment administered from the initial diagnosis to the first relapse or progression. The surgical extent was classified as complete resection with negative margins (R0 resection), gross total resection (resection of all gross visible disease but with microscopic residual disease present), or debulking (gross residual disease present). Chemotherapy was categorized into regimens containing platinum or regimens containing anthracyclines and nonplatinum alkylating agents. Progression-free survival (PFS) was measured as the time from the initial diagnosis of NMC until the time of first disease relapse, progression, or death or until last contact if none of these events occurred. Overall survival (OS) was defined as the time from diagnosis until the time of death or last contact. Clinical responses to initial therapies were classified as complete or partial responses, stable disease, or progressive disease according to the clinical judgment of the treating physician. The confirmation of a diagnosis was obtained from pathology reports, and the actual histology was reviewed when available. Cases were classified into 1 of 3 histopathologic categories: carcinoma with squamous differentiation, carcinoma without squamous differentiation, and other histology.
Statistical Analysis
Analyses were conducted to investigate factors potentially associated with PFS or OS with Kaplan-Meier plots and log-rank tests. Two-year PFS and OS point estimates were reported with 95% confidence intervals (CIs). Cox proportional hazards regression modeling to predict PFS and OS was conducted to generate unadjusted and adjusted results: individual predictors of PFS and OS were analyzed with and without the simultaneous inclusion of age and tumor size in the model. Hazard ratios (HRs) and 95% CIs were reported. SAS 9.4 was used.
RESULTS
Demographic and Tumor Characteristics
Demographic and tumor characteristics were available for all 48 patients. The diagnosis of HNNMC has increased dramatically since 2012 with an increasing proportion of adult cases (cases diagnosed at the age of 18 years or older; Fig. F1 1). The median age was 21.9 years (range, 0.1-81.7 years), and there was a female predominance (1.5:1). The tumor site had a sinonasal origin in 57%, and other sites included the nasopharynx (n 5 3), the oropharynx (n 5 1), the hypopharynx (n 5 1), the larynx (n 5 1), a salivary gland (n 5 2), and an unknown primary (n 5 5). The BRD4-NUT fusion was found in 86%. Histology was classified in 49% of the patients as carcinoma with squamous differentiation, whereas 43% had carcinoma without squamous differentiation, and 8% had other histology. As for the NMC diagnosis, we found that 16 of 46 patients (35%) for whom the initial and final diagnoses were known were in fact initially diagnosed with NMC. The original diagnoses for the remaining 30 patients (65%) are listed in Supporting Table 1 (see online supporting information) and include most commonly poorly differentiated carcinoma (n 5 8), poorly differentiated squamous carcinoma (n 5 6), and sinonasal undifferentiated carcinoma (n 5 5). At diagnosis, 26% had regional nodal metastases, 6% had distant metastases, and 12% had both. The average primary tumor size was 5.2 cm at diagnosis.
Treatment
Details of treatment were available for 39 of the 48 patients. All patients received surgery, radiation, or chemotherapy either as single agents or in combination as part of their initial management. Because no established Figure 1 . Diagnosis of head and neck NUT midline carcinoma in adult and pediatric patients by year.
treatment regimen exists for NMC, treatment was selected on the basis of physician discretion and individual factors. Among the 24 patients who underwent surgery, 5 patients had a complete tumor resection with negative margins, 9 had a gross total resection, and 10 underwent debulking (subtotal resection). Twenty-nine patients received radiotherapy. Thirty-three patients received chemotherapy, and 27 of these patients received a platinum agent.
The majority of the patients received intensive initial multimodality therapy (n 5 28 [72%]), which consisted of various combinations of surgery, chemotherapy, and radiotherapy. For the purposes of this study, treatment was classified into 1 of 3 main categories according to the initial sequencing strategy of therapeutic modalities: 1) initial surgery with or without adjuvant chemoradiation or adjuvant radiation (n 5 22 [56%]), 2) initial radiation with or without concurrent chemotherapy (chemoradiation; n 5 6 [15%]), or 3) initial chemotherapy alone or followed by surgery, radiation, or chemoradiation (n 5 11 [28%]). One of the 22 patients who underwent initial surgery had surgery alone without adjuvant therapy, 19 received postoperative adjuvant chemoradiation with concurrent chemotherapy with agents such as cisplatin, and 2 patients received postoperative adjuvant radiation alone. Six patients underwent initial definitive radiation-based therapy: 3 of these patients received radiation alone, and 3 patients received radiation concurrently with chemotherapy. Eleven patients initially received chemotherapy: 7 received chemotherapy alone, 2 received subsequent surgery, 1 received subsequent radiation alone, and 1 went on to receive chemoradiation.
Outcomes
Outcome data were available for 40 of the 48 cases (Table  T1 1). The median PFS was 6.6 months (range, 4.7-8.4 months). The median OS was 9.7 months (range, 6.6-15.6 months). The 2-year PFS rate was 26% (95% CI, 13%-40%). The 2-year OS rate was 30% (95% CI, 16%-46%). The median follow-up was 8.3 months (range, 2.1-30.0 months) for the entire cohort and 19.2 months (range, 2.0-79.0 months) for living patients. There was no statistically significant difference in PFS or OS by age, sex, tumor location, size, histology, presence of neck lymph node involvement, or BRD4-NUT translocation ( Table 1) .
The presence of distant metastases was associated with 2-year PFS and OS rates of 0%. The pattern of treatment failure at first relapse or progression was evaluable for 21 cases; 3 patients (14%) had isolated locoregional disease, 7 (33%) had isolated distant disease, and 11 (52%) developed both locoregional and distant disease.
A clinical response to the initial therapy was reported for 38 patients. The best response to the initial therapy was a complete response in 10 patients, a partial response in 9 patients, and progressive disease in 19 patients. Eight of the 10 patients with a complete response were alive at the last follow-up with no evidence of disease (NED): 1 patient had surgery alone (NED at 23 months), 1 patient had surgery and then adjuvant radiation (NED at 72 months), and 6 patients had surgery followed by postoperative adjuvant chemoradiation (NED at 14, 15, 17, 18, 35, and 78 months). The remaining 2 patients with a complete response to initial therapy had progression 6 months after their diagnosis and died of their disease (OS of 8 and 9 months), and both patients had completed treatment with surgery followed by postoperative adjuvant chemoradiation. In comparison, only 3 of the 9 patients with a partial response were alive at the last follow-up, and none of the 19 patients with progressive disease were alive at the last follow-up. The best response to the initial therapy was associated with statistically significantly higher PFS (P < .0001) and OS (P < .0001; Table 1 ). The response was not significantly associated with age, sex, tumor histology, NUT translocation subtype, tumor location, or neck lymph node involvement.
Impact of Therapy
Surgical resection, the extent of surgical resection, negative margins, and the best response to the initial treatment strategy were significantly associated with improved PFS and OS (Table 1) in our retrospective analysis of this small patient cohort. Patients who underwent surgery had a 2-year OS rate of 50%, whereas those who did not had a 2-year OS of 7% (P 5 .003). Notably, the extent of surgical resection was significantly associated with PFS and OS (Table 1) in a graded fashion: the 2-year OS for patients who achieved negative margins was 80%, the 2-year OS with gross total resection with positive margins was 44%, the 2-year OS with debulking was 37%, and the 2-year OS with no surgery was 7% (Table 1) . Radiotherapy and chemotherapy, including the type of chemotherapy (anthracycline or cisplatin), were not associated with differences in PFS or OS.
The sequencing of the initial treatment strategy was also statistically significantly associated with survival. Patients who initially underwent surgery with or without subsequent radiation-based therapy had a 2-year OS rate of 50% (11 of 22; 95% CI, 27%-79%), whereas patients who initially had chemotherapy followed by subsequent surgery or radiation had a 2-year OS of 18% (2 of 11; 95% CI, 3%-44%), and patients who initially underwent radiation with or without chemotherapy had a 2-year OS of 0% (0 of 6; P 5 .04; Fig.  F2 2). To identify factors independently prognostic of PFS and OS, a multivariate analysis of selected predictors of PFS and OS was performed with and without adjustments for age and tumor size (Table  T2 2). The initial treatment strategy incorporating initial surgery remained predictive of OS even after adjustments for age and tumor size (HR, 0.35; 95% CI, 0.13-0.90; P 5 .03; Table 2 ). Initial surgery was also independently prognostic for OS (HR, 0.36; 95% CI, 0.15-0.83; P 5 .01) and PFS (HR, 0.24; 95% CI, 0.09-0.68; P 5 .007) after adjustments for neck lymph node involvement. Complete resection with negative margins was also independently predictive of PFS and OS after adjustments for age and tumor size ( Table 2) .
In an exploratory analysis, we examined the interaction between initial surgery and tumor size to determine whether the effect of surgery might depend on the size of the tumor. An interaction between initial surgery and tumor size was present for PFS (P 5 .06) and OS (P 5 .02), Fig.  F3 3). For tumors that were 6 cm or larger, initial surgery was not associated with a significant protective effect on PFS (HR, 1.17; 95% CI, 0.27-5.16; P 5 .83) or OS (HR, 1.2; 95% CI, 0.26-5.13; P 5 .84; Fig. 3 ). Although this is intriguing, we recognize that strong conclusions cannot be drawn because of the small sample size.
DISCUSSION
NMC is an extremely aggressive and rare genetically defined subtype of squamous carcinoma arising from the HN in approximately 45% of cases. To define the clinical presentation and optimal treatment approaches, we performed a retrospective analysis of all HNNMC cases in the International NUT Midline Carcinoma Registry. Our study represents the largest HNNMC cohort reported to date because the existing literature regarding HNNMC has been primarily restricted to isolated case reports with limited treatment or follow-up data. [15] [16] [17] [18] [19] [20] [21] The frequency of diagnosis of HNNMC appears to be increasing, particularly since 2012, and the proportion of adults with this diagnosis is also rising. This may be an effect of a reporting bias due to the recent description of NMC in the HN 8, 9, 22 and the improved diagnostic availability of a simple, highly sensitive and specific immunohistochemical stain for the NUT gene product using a commercially available clinical antibody. 5 The increasing incidence of diagnosis, coupled with the fact that nearly two-thirds of HNNMC cases in this cohort were initially misdiagnosed, suggests that NMC remains underrecognized. We found that the most common incorrect initial histologic diagnoses preceding the subsequent diagnosis of HNNMC Figure 2 . Overall survival according to the initial treatment strategy. The probability of overall survival is presented for patients with head and neck NUT midline carcinoma according to the initial treatment strategy, which consisted of initial radiation, initial chemotherapy, or initial surgery. were poorly differentiated carcinoma (n 5 8) and poorly differentiated squamous carcinoma (n 5 6). This suggests that clinicians should consider NMC in any HN carcinoma with a poorly differentiated component or with clinically aggressive behavior. Most HNNMC patients present with locally advanced disease, and the average tumor size is more than 5 cm at the time of diagnosis. Unlike most HN cancers, HNNMC appears to affect women more than men for unclear reasons. Survival outcomes are poor with a median survival of 9.7 months, although this appears to be better than the outcomes for thoracic NMC according to a historical comparison. 7 Survival appears to be affected by the treatment selection and the initial therapeutic sequencing strategy. Initial surgical resection and the extent of surgical resection (negative margins) were significantly associated with PFS and OS. In our cohort, surgical resection appeared to be beneficial for survival for most patients, particularly for those with tumors less than 6 cm in size, and this association was independent of patient age and neck lymph node involvement. These data should be interpreted with caution because of the limited size of this cohort and the lack of prospective comparison. It is possible that because enrollment in the International NUT Midline Carcinoma Registry is voluntary and does not involve systematic testing of all HN squamous cell carcinomas for NUT rearrangement, patients in this registry cohort may not fully represent the behavior of all HNNMCs.
Initial radiation or chemotherapy was not associated with significantly improved survival outcomes; however, either may be important as adjuvant therapy. The incremental benefit and role of postoperative adjuvant therapy are unclear because all but 1 patient in our cohort that underwent surgical resection received postoperative adjuvant radiation or chemoradiation. Our findings are in keeping with accepted treatment paradigms used for other aggressive sinonasal tumors, such as sinonasal undifferentiated carcinomas, for which better survival outcomes and local control rates are achieved when complete surgical resection is incorporated into a multimodality treatment. 23 -25 HNNMC appears to be more aggressive (2-year OS rate in our series, 30%) in comparison with sinonasal undifferentiated carcinoma (2-year OS rate, 47%
24
; 5-year OS rate, 45% 26 , and this highlights the need for a prompt multidisciplinary evaluation at specialized centers (HN surgical, radiation, and medical oncology) for all patients diagnosed with HNNMC.
Our findings reveal that the initial treatment selection and sequencing are critical in HNNMC because the response to the initial therapy was associated with improved survival. In our cohort, only 10 patients achieved a complete response to the initial therapy, and all initially underwent surgery. The only long-term survivors in our series (with survival of 35, 72, and 78 months) were those who initially received surgery. Again, despite these compelling findings, any interpretation should be made with caution because of the small size and retrospective nature of the study.
No other clinical or pathologic features, including the NUT translocation type, or treatment approaches, including the type of chemotherapy regimen, were associated with survival outcomes. The lack of an association of the outcome with the translocation type may be due to a lack of sufficient statistical power because the majority of the patients in our series had a BRD4-NUT translocation (86%); this left a minority with BRD3-NUT (n 5 2), Figure 3 . Influence of surgical resection on (A) progression-free survival and (B) overall survival for patients with head and neck NUT midline carcinoma according to the primary tumor size (<6 or 6 cm).
NSD3-NUT (n 5 2), and NUT-variant fusions (n 5 2). Notably, 2 of the 3 long-term survivors had BRD3-NUT tumors, and a borderline statistically significant difference in PFS and OS was observed when we compared patients with BRD3-NUT with patients with all other translocation types (P 5 .05). In our series, many systemic therapy regimens, including platinums, anthracyclines, and alkylating agents in various combinations, were used; however, no agent was associated with improved outcomes. The overall unsatisfactory treatment outcomes for this genomically driven tumor highlight the rationale for molecularly targeted therapies as a promising therapeutic strategy. Acetyl-histone mimetic drugs, termed BET or bromodomain inhibitors, act by competitively inhibiting the binding of BRD-NUT to chromatin and preventing its ability to activate these oncogenic target genes. 10, 27 First-in-class, direct-acting BET inhibitors are active in NMC xenograft models and humans. 13, 27 At least 5 phase 1 clinical trials in the United States (NCT01587703, NCT01987362, and NCT02431260) and Europe (NCT02259114 and NCT01587703) are currently evaluating bromodomain inhibitors in patients with NMC. In addition, histone deacetylase inhibitors have exhibited preclinical and clinical activity in NMC, and there is a clinical trial in the United States enrolling NMC patients for whom bromodomain inhibitors have failed (NCT02307240). 12, 28 If they are deemed effective, it will be critical to incorporate these novel agents into HNNMC treatment paradigms.
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